Discover

HBIO
Harvard Bioscience, Inc.
6.05
2 x 4.47
2 x 7.75
bid
ask
-
0.10
1.63%
2 @ 04:00 PM
6.08 +0.03 (0.50%)
Ytd-9.70%
1y34.44%
5.99
day range
6.28
3.80
52 week range
9.40
Open6.15Prev Close6.15Low5.99High6.28Mkt Cap27.29M
Vol20.45KAvg Vol40.25KEPS-2.15P/EN/AForward P/E14.00
Beta1.31Short Ratio2.66Inst. Own75.99%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1050-d Avg6.13200-d Avg5.761yr Est6.25
Earning
DateForEstimateReportedSurprisesurprise %
2024-11-072024-090.05-0.02-0.07-140.00%
2024-08-082024-060.05-0.03-0.08-160.00%
2024-08-082024-060.05N/AN/AN/A
2024-05-072024-030.020.02N/AN/A
2024-05-072024-030.02N/AN/AN/A
2024-03-072023-120.050.01-0.04-80.00%
Upgrade / Downgrade
DateFirmActionFromTo
2023-06-22BenchmarkUpgradeSpeculative BuySpeculative Buy
2023-04-26BenchmarkUpgradeBuy
2023-04-26KeybancUpgradeOverweight
2023-03-10BenchmarkUpgradeBuy
2022-11-09KeybancUpgradeOverweight
2022-08-05KeybancUpgradeOverweight
Profile
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Insider Holder
DateNameRelationQuantityDescription
2024-03-04COTE JENNIFERChief Financial Officer168.74KStock Award(Grant)
2024-05-20EADE KATHERINE ANNEDirector311.13KStock Award(Grant)
2024-05-20EDRICK ALAN IANDirector273.91KStock Award(Grant)
2024-06-12GREEN JAMES WChief Executive Officer3.11MPurchase
2024-05-20LOEWALD THOMAS WDirector295.31KStock Award(Grant)
2024-05-20LOY BERTRANDDirector556.21KStock Award(Grant)
Institution Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29Blackrock Inc.2.92M6.12M6.69%
2024-09-29Punch & Associates Investment Management, Inc.2.77M5.82M6.36%
2024-09-29Harvey Partners, LLC2.72M5.70M6.22%
2024-09-29AMH Equity Ltd.2.39M5.02M5.48%
2024-09-29Vanguard Group Inc2.15M4.52M4.94%
2024-09-29Granahan Investment Management LLC1.87M3.92M4.28%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29Vanguard Total Stock Market Index Fund1.26M2.65M2.89%
2024-09-29Heartland Value Fund1.20M2.52M2.75%
2024-10-30iShares Russell 2000 ETF952.12K2.00M2.18%
2024-09-29Royce Micro-Cap Fund647.02K1.36M1.48%
2024-09-29Vanguard Extended Market Index Fund579.99K1.22M1.33%
2024-09-29JNL Series Trust-JNL/Multi Manager Small Cap GrowthFd453.80K952.99K1.04%
Split
SplitDate
1 : 102026-03-16
1319 : 10002013-11-04
1.319 : 12013-11-03